Stocktoria
FibroBiologics, Inc. FBLG
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2024-01-31
FibroBiologics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| R&D expense | $7.4M | $4.5M | $2.4M | $1.1M |
| Operating income | -$16.6M | -$13.7M | -$8.9M | -$4.5M |
| Interest expense | — | — | $147,000 | $654,000 |
| Income tax | $0 | $0 | $0 | $0 |
| Net income | -$18.6M | -$11.2M | -$16.5M | -$5.1M |
| EPS (diluted) | $-0.42 | $-0.34 | $-0.68 | $-0.18 |
| Operating cash flow | -$16.4M | -$11.9M | -$6.4M | -$4.1M |
| Free cash flow | -$16.7M | -$12.1M | -$6.9M | — |
| Cash & equivalents | $4.9M | $14.0M | $9.2M | $2.3M |
| Total assets | $9.6M | $16.4M | $11.8M | $4.8M |
| Total liabilities | $3.5M | $13.7M | $10.6M | $8.8M |
| Shareholders' equity | $6.2M | $2.7M | $1.3M | -$4.0M |
Source: SEC EDGAR filings · CIK 0001958777 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.